On January 16th, 2025, GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led by Evidity Health Capital and joined by Accelmed Partners. Current investors MVM Partners, Gilde Healthcare and Medtech Venture Partners also participated in the funding.
GT Medical Technologies is a medical device company focused on improving the lives of patients with brain tumors. The company’s flagship product, GammaTile® offers a new approach by delivering therapeutic radiation at the tumor site immediately after tumor removal. The funds raised in Series D financing will help advance the completion of ROADS clinical study that is focused on GammaTile for newly diagnosed brain metastases, and the GESTALT clinical trial for patients with newly diagnosed glioblastomas (GBMs) [1]. The funding will further support the ongoing commercialization of GammaTile®.
GT Medical Technologies’s raise comes at a time of positive start for initial public offerings (IPOs) in 2025, with Sionna Therapeutics and Odyssey Therapeutics launching bids for IPOs following the steps of Maze Therapeutics and Metsera. As the federal reserve steps further into the easing cycle in 2025 with declining interest rates and a potential ease of inflation, we hope to see a rebound in interest from investors not just in companies that are post-clinical, but also in companies that are pre-clinical.
Editor: Brenden S. Gingrich, Ph.D.
Subscribe for News and Updates
